Osteonecrosis News and Research

RSS
FDA reviews Amgen’s prostate cancer drug Xgeva

FDA reviews Amgen’s prostate cancer drug Xgeva

New discovery paves way for genetic screening test

New discovery paves way for genetic screening test

FDA invites Amgen for ODAC meeting on XGEVA sBLA to treat castration-resistant prostate cancer

FDA invites Amgen for ODAC meeting on XGEVA sBLA to treat castration-resistant prostate cancer

Adjuvant zoledronic acid shows promise against ER-positive premenopausal breast cancer

Adjuvant zoledronic acid shows promise against ER-positive premenopausal breast cancer

Novartis to showcase 160 presentations on breast cancer, hematological disease drugs at SABCS and ASH

Novartis to showcase 160 presentations on breast cancer, hematological disease drugs at SABCS and ASH

Amgen's XGEVA delays onset of bone metastases in men with prostate cancer

Amgen's XGEVA delays onset of bone metastases in men with prostate cancer

Merck wins fourth FOSAMAX trial

Merck wins fourth FOSAMAX trial

Amgen's Prolia receives FDA approval for new indications to treat cancer patients

Amgen's Prolia receives FDA approval for new indications to treat cancer patients

FDA reviews safety issues of bisphosphonates for osteoporosis

FDA reviews safety issues of bisphosphonates for osteoporosis

EC grants marketing authorization for Amgen's XGEVA to prevent skeletal-related events

EC grants marketing authorization for Amgen's XGEVA to prevent skeletal-related events

Amgen files sBLA for XGEVA with FDA to treat castrate-resistant prostate cancer

Amgen files sBLA for XGEVA with FDA to treat castrate-resistant prostate cancer

Health Canada approves Tasigna for newly diagnosed Philadelphia chromosome-positive CML

Health Canada approves Tasigna for newly diagnosed Philadelphia chromosome-positive CML

Celgene announces results of REVLIMID, docetaxel/prednisone phase II combination study on mCRPC

Celgene announces results of REVLIMID, docetaxel/prednisone phase II combination study on mCRPC

EMA CHMP recommends positive opinion for marketing authorization of Amgen's XGEVA

EMA CHMP recommends positive opinion for marketing authorization of Amgen's XGEVA

Amgen announces primary results from XGEVA Phase 3 trial in castrate-resistant prostate cancer

Amgen announces primary results from XGEVA Phase 3 trial in castrate-resistant prostate cancer

Prolia associated with greater adherence than alendronate in postmenopausal women with osteoporosis

Prolia associated with greater adherence than alendronate in postmenopausal women with osteoporosis

The Lancet journal publishes XGEVA Phase 3 study results against prostate cancer, bone metastases

The Lancet journal publishes XGEVA Phase 3 study results against prostate cancer, bone metastases

Amgen announces publication of XGEVA Phase 3 study results against solid tumors in Journal of Clinical Oncology

Amgen announces publication of XGEVA Phase 3 study results against solid tumors in Journal of Clinical Oncology

State court jury rules in favor of Merck in FOSAMAX trial

State court jury rules in favor of Merck in FOSAMAX trial

Oral bisphosphonates outweigh the risk associated with jaw disease

Oral bisphosphonates outweigh the risk associated with jaw disease